New insider activity at Immuneering ( (IMRX) ) has taken place on January 21, 2026.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CBO Brakewood Harold Eugene has made a notable move in Immuneering stock, purchasing 5,250 shares in a transaction valued at $24,990, signaling increased insider commitment to the company.
Recent Updates on IMRX stock
Over the last 24 hours, Immuneering’s stock has been highly volatile, trading down about 40% to roughly $4.96 despite the company releasing updated Phase 2a data for its MEK inhibitor atebimetinib in first-line pancreatic cancer. The new 12‑month results showed a 64% overall survival rate with median overall survival not yet reached and median progression-free survival of 8.5 months, broadly in line with some competing regimens but potentially with a safety edge that could make the drug better suited for frailer patients. Analysts’ latest views and price targets are being driven primarily by this clinical update: they are reassessing the risk‑reward based on the strength of the survival benefit versus benchmarks, the durability of the separation from historical standard-of-care data, the comparable efficacy but possible tolerability advantage versus emerging competitors, and management’s clarified development path, including alignment with FDA and EMA on a pivotal Phase 3 design and plans to start the MAPKeeper 301 trial in mid‑2026. At the same time, AI‑driven and human analyses note that weak current fundamentals (minimal revenue, continued losses, and cash burn) and limited valuation support temper the otherwise encouraging clinical and regulatory outlook, helping explain why sentiment and targets are being refined rather than uniformly upgraded, even as the market reacts sharply to the news.
Spark’s Take on IMRX Stock
According to Spark, TipRanks’ AI Analyst, IMRX is a Neutral.
The score is held back primarily by weak financial performance (limited revenue, large losses, and sustained cash burn) and bearish technicals (trading below key moving averages with low RSI). Offsetting these are positive earnings-call fundamentals, including encouraging clinical outcomes, an extended cash runway into 2029, and pipeline advancement plans, while valuation is difficult to assess due to negative earnings and no dividend.
To see Spark’s full report on IMRX stock, click here.
More about Immuneering
YTD Price Performance: -27.36%
Average Trading Volume: 1,789,959
Technical Sentiment Signal: Buy
Current Market Cap: $295.7M